Why BioNTech Stock Crushed the Market Today The company might be close to commercializing its most advanced pipeline program.
Shots Fired! After RFK Jr.'s Senate Grilling, Will Pfizer, Moderna Survive The Battle In D.C.? It's unprecedented times for the Covid vaccine market, experts say. And Pfizer and Moderna remain under significant pressure.
BioNTech Surges 10% On Promising Test Results For Its Cancer Smart Bomb The company's DualityBio-partnered drug met the pre-specified bar for success in a pivotal study.
BioNTech Advances On Positive Phase 3 Breast Cancer Drug Data BioNTech and DualityBio reported Phase 3 success for trastuzumab pamirtecan in HER2 breast cancer, setting stage for regulatory submission in China.
Robert Kennedy Jr.'s Leadership Can Only Bring More 'Harm,' Says Top Ex-CDC Official: 'Undoing Of Vaccination' In Works Daskalakis resigned due to political interference in CDC, fears harm will come from new direction. CDC leaders also resign in protest.
RFK Jr. Rescinds Emergency Authorizations For COVID-19 Vaccines FDA approves Pfizer, Moderna, and Novavax Covid vaccines for high-risk groups as emergency authorizations end and vaccines transition to full marketing.
RFK Jr. Makes Good On Promise To End Covid Vaccine Mandate. BioNTech Tumbles. Shares of one vaccine-maker are under pressure on Robert F. Kennedy Jr.'s move on Wednesday.
Trump Administration Plans To Pull COVID-19 Vaccines Off Market 'Within Months' The Trump administration may remove COVID-19 vaccines from the U.S. market as RFK Jr.'s allies gain influence at HHS, with a new vaccine task force led by a known skeptic.
3 Reasons Pfizer's 7%-Yielding Dividend Is Getting Safer This big pharma company's juicy dividend is looking even more attractive.
CDC Shooting Linked To Suspect's COVID-19 Vaccine Beliefs, Former Staff Blame RFK Jr. Hostility Toward Agency CDC shooting tied to anti-vaccine beliefs sparks warnings from staff, as leaders clash over the future of mRNA vaccines and federal health policy.
Former Surgeon General Slams RFK Jr. Over mRNA Cuts, Says US 'Conceding To China,' 2 Million Lives At Risk Adams warns cutting funding for mRNA vaccine research will cost lives, derail medical progress, and give China an advantage.
BioNTech SE (NASDAQ:BNTX) Q2 2025 Earnings: Revenue Surges 68.5%, Losses Narrower Than Expected BioNTech Q2 2025 earnings beat revenue estimates with $255.99M, narrowing losses to -$1.57 EPS. Shares rose 2% pre-market as oncology pipeline advances.
Pfizer's Ascent Signals Broader Health Sector Resilience Amidst Innovation Wave In a notable shift, shares of Pfizer (
NYSE: PFE ) have recently edged higher, reflecting a burgeoning strength within the broader health sector. This uptick signals a renewed investor confidence in the pharmaceutical giant and the wider healthcare industry, which has been navigating a complex landscape of regulatory scrutiny, patent expirations,
Moderna's Key Patent Win Overshadowed By Gloomy Outlook Moderna beat Q2 earnings and revenue estimates, narrowed its annual forecast, won a key patent case, and plans to cut 10% of its global workforce.
Bristol Myers Cuts Earnings Outlook As Legacy Drugs Face Generic Erosion Bristol Myers beat Q2 sales expectations but cut its 2025 EPS forecast as strategic charges and legacy product declines weighed on earnings.
